Cytek Biosciences, Inc. CTKB Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Thermo Fisher ScientificTMO

——

10x Genomics, Inc.TXG

——

FortiveFTV

——

Other financials

Income statement

See full

Revenue$44.1M+6.5%

Gross profit$21.3M+5.4%

Operating income-$18.5M-23.3%

Net income-$18.9M-65.5%

EPS (diluted)-$0.15-66.7%

Balance sheet

See full

Cash & equivalents$31.8M-66.6%

Total debt$16.8M+40.9%

Total equity$327.6M-13.7%

Total assets$449.1M-6.9%

Cash flow

See full

Operating cash flow-$2.7M-2,089%

CapEx$2.2M+155%

Free cash flow-$4.9M-403%

Valuation

See full

Market cap$577.27M+54.5%

Enterprise value$562.23M+93.7%

P/S2.8×+0.9×

Profitability

See full

Gross margin51.7%-3.2pp

Operating margin-21.5%—

Net margin-36.2%—

FCF margin-6.2%-15.1pp

Returns & leverage

See full

Return on equity-20.9%—

Debt / equity0.1×0.0×

Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s deferred revenue, net of current portion?: Cytek Biosciences, Inc. (CTKB) reported deferred revenue, net of current portion of $17.67M in Q1 2026.